CG
CRSP icon

Cutler Group’s CRISPR Therapeutics CRSP Stock Holding History

Cutler Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$47K Buy
700
+500
+250% +$35.8K 0.02% 699
2023
Q4 		$12K Sell
200
-1,800
-90% -$99.5K ﹤0.01% 2276
2023
Q3 		$90K Sell
2,000
-860
-30% -$44.4K 0.01% 1172
2023
Q2 		$160K Buy
2,860
+2,160
+309% +$123K 0.02% 721
2023
Q1 		$31K Buy
+700
New +$34K ﹤0.01% 1648
2022
Q4 		– Sell
-12,553
Closed -$666K – 4512
2022
Q3 		$820K Sell
12,553
-247
-2% -$17.9K 0.06% 363
2022
Q2 		$777K Sell
12,800
-10,668
-45% -$627K 0.05% 396
2022
Q1 		$1.47M Buy
23,468
+730
+3% +$45.8K 0.08% 279
2021
Q4 		$1.72M Buy
22,738
+9,838
+76% +$859K 0.07% 290
2021
Q3 		$1.44M Buy
12,900
+2,320
+22% +$291K 0.06% 332
2021
Q2 		$1.71M Buy
10,580
+2,580
+32% +$314K 0.08% 280
2021
Q1 		$974K Sell
8,000
-4,760
-37% -$719K 0.05% 460
2020
Q4 		$1.95M Buy
12,760
+12,360
+3,090% +$1.46M 0.09% 216
2020
Q3 		$33K Buy
+400
New +$35.5K ﹤0.01% 2082
2020
Q2 		– Sell
-800
Closed -$46.8K – 4442
2020
Q1 		$33K Sell
800
-1,300
-62% -$67.1K ﹤0.01% 1978
2019
Q4 		$127K Buy
+2,100
New +$115K 0.01% 1071
2018
Q2 		– Sell
-6,097
Closed -$347K – 4285
2018
Q1 		$278K Buy
+6,097
New +$252K 0.02% 647
2017
Q4 		– Sell
-600
Closed -$11.4K – 5034
2017
Q3 		$10K Buy
600
+263
+78% +$4.77K ﹤0.01% 3794
2017
Q2 		$5K Buy
+337
New +$5.57K ﹤0.01% 4809

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's CRSP Position: Q1 2024 in Review

Cutler Group increased its CRISPR Therapeutics (CRSP) stake by 250% in Q1 2024, buying an estimated $35.8K and bringing the position to 700 shares worth $47K. The position accounts for 0.02% of the portfolio, ranked #699.

Cutler Group first reported a position in CRSP in Q2 2017 and has held it in 19 quarters since. The position peaked at $1.95M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cutler Group held 700 shares of CRISPR Therapeutics worth $47K as of Q1 2024.
  • Cutler Group bought 500 CRISPR Therapeutics shares in Q1 2024, an estimated $35.8K.
  • CRISPR Therapeutics made up 0.02% of Cutler Group's portfolio in Q1 2024, its #699 holding.
  • Cutler Group first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 19 quarters since.
  • Cutler Group's CRISPR Therapeutics position peaked at $1.95M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.